Drugs / PF-06438179
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01844804 | May → Nov 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02222493 | Aug 2014 → Jun 2016 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-09-16 | Pfizer | Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab) pfizer.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06438179 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02222493 ↗ |
| Known as | GP1111 | “Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid...” PMID 31939063 ↗ Apr 20201“A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).” PMID 29504427 ↗ Mar 2018 |
| Known as | PF-SZ-IFX | “Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid...” PMID 31939063 ↗ Apr 2020 |
| Route | Intravenous | “PF-06438179 will be administered by intravenous infusion” NCT02222493 ↗ |